ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma

Phase 1

Completed

Conditions: Malignant Glioma
Glioblastoma Multiforme

Interventions: Drug: ABT-414
Radiation: Whole Brain Radiation
Drug: Temozolomide

First Posted Date: 2015-10-29

Last Posted Date: 2020-09-03

Lead Sponsor: AbbVie

Target Recruit Count: 53

Registration Number: NCT02590263

Locations: 🇯🇵
University of Tsukuba Hospital /ID# 140433, Tsukuba-shi, Ibaraki, Japan
🇯🇵
Osaka University Hospital /ID# 140438, Suita-shi, Osaka, Japan
🇯🇵
Iwate Medical University Hospital /ID# 149145, Shiwa-gun, Iwate, Japan

and more 19 locations

Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)

Completed

Conditions: Chronic Hepatitis C

First Posted Date: 2015-10-21

Last Posted Date: 2019-06-05

Lead Sponsor: AbbVie

Target Recruit Count: 173

Registration Number: NCT02582658

The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Ombitasvir/paritaprevir/ritonavir
Drug: Dasabuvir
Drug: Ribavirin

First Posted Date: 2015-10-21

Last Posted Date: 2019-05-06

Lead Sponsor: AbbVie

Target Recruit Count: 101

Registration Number: NCT02582671

A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults

Phase 3

Completed

Conditions: Hepatitis C Infection
Hepatitis C Virus

Interventions: Drug: ombitasvir/paritaprevir/ritonavir
Drug: dasabuvir

First Posted Date: 2015-10-21

Last Posted Date: 2021-07-30

Lead Sponsor: AbbVie

Target Recruit Count: 166

Registration Number: NCT02582632

The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation

Completed

Conditions: HIV-1 Infection

Interventions: Drug: lopinavir/ritonavir
Drug: lamivudine

First Posted Date: 2015-10-20

Last Posted Date: 2019-06-06

Lead Sponsor: AbbVie

Target Recruit Count: 216

Registration Number: NCT02581202

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Ombitasvir/paritaprevir/ritonavir
Drug: Dasabuvir
Drug: Ribavirin

First Posted Date: 2015-10-20

Last Posted Date: 2019-03-27

Lead Sponsor: AbbVie

Target Recruit Count: 565

Registration Number: NCT02581189

Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium

Completed

Conditions: Chronic Hepatitis C, Genotype 1 or 4

Interventions: Drug: Ombitasvir/paritaprevir/ritonavir
Drug: Dasabuvir
Drug: Ribavirin

First Posted Date: 2015-10-20

Last Posted Date: 2019-05-06

Lead Sponsor: AbbVie

Target Recruit Count: 314

Registration Number: NCT02581163

The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects

Completed

Conditions: Hepatitis C Virus

First Posted Date: 2015-10-20

Last Posted Date: 2021-12-08

Lead Sponsor: AbbVie

Target Recruit Count: 344

Registration Number: NCT02581020

Locations: 🇯🇵
Kurume University Hospital /ID# 152123, Kurume-shi, Fukuoka, Japan
🇯🇵
Kawasaki Municipal Tama Hospit /ID# 153546, Kawasaki, Japan
🇯🇵
Hiroshima University Hospital /ID# 152232, Hiroshima-shi, Hiroshima, Japan

and more 50 locations

Post-Marketing Surveillance of Humira in Korean Pediatric Crohn's Disease (CD) Patients Under the "New-Drug Re-examination"

Completed

Conditions: Pediatric Crohn's Disease

First Posted Date: 2015-10-16

Last Posted Date: 2018-12-19

Lead Sponsor: AbbVie

Target Recruit Count: 143

Registration Number: NCT02578238

Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment

Phase 1

Terminated

Conditions: Alzheimer's Disease
Mild Cognitive Impairment

Interventions: Drug: ABT-957
Other: Placebo

First Posted Date: 2015-10-12

Last Posted Date: 2021-07-06

Lead Sponsor: AbbVie

Target Recruit Count: 8

Registration Number: NCT02573740

Locations: 🇺🇸
Site Reference ID/Investigator# 149481, Dallas, Texas, United States
🇺🇸
Site Reference ID/Investigator# 143180, Cypress, California, United States
🇺🇸
Site Reference ID/Investigator# 143178, Orlando, Florida, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy